Abstract The apoptosis repressor with caspase recruitment domain (ARC) protein is known to suppress both intrinsic and extrinsic apoptosis. We previously reported that ARC expression is a strong, independent adverse prognostic factor in acute myeloid leukemia (AML). Here, we investigated the regulation and role of ARC in AML. ARC expression is upregulated in AML cells co-cultured with bone marrow-derived mesenchymal stromal cells (MSCs) and suppressed by inhibition of MAPK and PI3K signaling. AML patient samples with RAS mutations (N = 64) expressed significantly higher levels of ARC than samples without RAS mutations (N = 371) (P = 0.016). ARC overexpression protected and ARC knockdown sensitized AML cells to cytarabine and to agents that selectively induce intrinsic (ABT-737) or extrinsic (TNF-related apoptosis inducing ligand) apoptosis. NOD-SCID mice harboring ARC-overexpressing KG-1 cells had significantly shorter survival than mice injected with control cells (median 84 vs 111 days) and significantly fewer leukemia cells were present when NOD/SCID IL2Rc null mice were injected with ARC knockdown as compared to control Molm13 cells (P = 0.005 and 0.03 at 2 and 3 weeks, respectively). Together, these findings demonstrate that MSCs regulate ARC in AML through activation of MAPK and PI3K signaling pathways. ARC confers drug resistance and survival advantage to AML in vitro and in vivo, suggesting ARC as a novel target in AML therapy.
Introduction
The apoptosis repressor with caspase recruitment domain (ARC) protein was originally described in normal heart [1, 2] , brain [3] , and muscle [4] cells. It protects these cells from apoptosis induced by various stressors. ARC is unique since it suppresses the activation of both the intrinsic and extrinsic apoptosis pathways [4] [5] [6] [7] [8] . ARC is overexpressed in various malignant cells, and this expression is associated with disease progression and poor outcomes [5, [9] [10] [11] [12] [13] . Furthermore, ARC was found to be induced by RAS to promote tumorigenesis and metastasis in breast and other cancer cells [12] [13] [14] [15] .
As part of our ongoing search for prognostic markers and clinically relevant therapeutic targets in acute myeloid leukemia (AML), we recently analyzed ARC expression by reverse-phase protein array (RPPA) in samples obtained from patients (n = 511) with newly diagnosed AML. This analysis identified ARC as a novel adverse prognostic factor in AML with the highest negative impact. Specifically, high ARC protein expression predicted a shorter overall survival and poor treatment outcome in patients with AML [16] .
In addition to intrinsic apoptosis resistance in leukemia cells, external factors in the bone marrow (BM) microenvironment where leukemic cells reside contribute to drug resistance and disease relapse. BM-derived mesenchymal stromal cells (MSCs) are known to secrete various growth factors, interact with leukemia cells, and provide a sanctuary to protect leukemia cells from apoptosis induction by various therapeutic agents via activation of survival signaling pathways [17] and induction of anti-apoptotic proteins [18] [19] [20] . Nevertheless, the mechanisms of ARC regulation in AML cells, and the role of ARC in AML cell survival and drug resistance are largely unknown.
In this study, we investigated the regulation of ARC in AML by signaling pathways and by MSCs from the BM microenvironment. Using AML cells in which ARC expression was genetically modified, we studied the role of ARC in drug resistance of AML cells. We establish that ARC is upregulated by MSCs through MAPK and PI3K signaling in AML cells. Furthermore, we demonstrate that ARC protects AML cells from apoptosis induced by either chemotherapy or agents that selectively induce intrinsic or extrinsic apoptosis, thus conferring survival advantage to AML both in vitro and in vivo in mouse models.
Materials and methods

Cells and cell cultures
OCI-AML3 cells were kindly provided by Dr. M. Minden (Ontario Cancer Institute, Ontario, Canada), KG-1 cells were purchased from the American Type Culture Collection (Manassas, VA, USA), and Molm13 cells were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). Cells were cultured in RPMI 1640 medium supplemented with 10 % heat-inactivated fetal calf serum (FSC), 2 mM L-glutamine, 100 U/ml penicillin, and 100 lg/ml streptomycin. MSCs were isolated from BM of healthy subjects as previously described [21] .
ARC knockdown in AML cells ARC was knocked down by lentiviral transduction using gene-specific shRNAmir-green fluorescent protein (GFP)-expressing transfer vectors: clone V3LHS_337663, targeting residues 732-750 on RefSeq NM_003946.4, for OCI-AML3 cells and clone V3LHS_337662, targeting residues 217-235 on RefSeq NM_003946.4, for Molm13 cells (Open Biosystems, Huntsville, AL, USA). Lentivirus was prepared by co-transfection of HEK293T cells (American type culture collection) with an equal molar mix of transfer vector and packaging plasmids (psPAX2 and pMD2.G; Addgene, Cambridge, MA, USA) using JetPrime transfection reagent as directed by the manufacturer (Polyplus, Illkirch, France). Fresh lentiviral supernatants were passed through 0.45-micron-pore surfactant-free cellulose acetate membranes and then used at once to infect leukemic cells by incubation overnight at 37°C in 5 % CO 2 . Infected cells were subjected to selection with puromycin (Invivogen, San Diego, CA, USA) starting at 1 lg/ml. In parallel, OCI-AML3 and Molm13 cells were transduced with lentivirus delivering a non-specific control vector (Open Biosystems). Knockdown (K/D) was verified by western blot analysis and by real-time RT-PCR.
ARC overexpression in KG-1 cells
The ARC coding sequence was excised from EGFP-Myp (kindly provided by Dr. S. Stamm, University of Kentucky, Lexington, KY, USA) with MluI-BglII and its ends filled in with Klenow before it was cloned into pCDH-CMV-MCS-EF1-copGFP (SystemBio, Mountain View, CA, USA) between the blunted NheI-NotI sites. The resulting lentiviral vector was designated pCDH-CMV-ARC-EF1-cop-GFP. KG-1 cells were infected with concentrated lentivirus transduced with either pCDH-CMV-ARC-EF1-copGFP or pCDH empty vector generated by a process similar to that just described; 8 lg/ml Polybrene (Sigma Chemical Co., St. Louis, MO, USA) was included to enhance lentiviral infections. A week after infection, stably transduced KG-1 cells were sorted by fluorescence activation (FACS) to obtain a homogeneous population of ARC overexpressing (O/E) CopGFP-positive cells.
Treatment of cells
OCI-AML3 cells were treated with MEK/ERK inhibitor PD0325901 (Cayman Chemical, Ann Arbor, MI, USA) or PI3K inhibitor LY294002 (Sigma) or BEZ235 (LC Laboratories, Woburn, MA, USA), and cells were collected for RNA purification, lysate preparation, or immunofluorescence staining. To transiently knockdown MAPK signaling, OCI-AML3 cells were transfected with MAP3K1siRNA (on Target Plus Smart pool; Thermo Scientific Dharmacon, Pittsburgh, PA, USA) by electroporation using an Amaxa apparatus (Amaxa Biosystems, Cologne, Germany) following the manufacturer's instructions. For OCI-AML3-MSCs co-culture experiments, MSCs were pre-plated at 5 9 10 3 /cm 2 for 24 h. OCI-AML3 cells were added (four times the number of MSCs). Cells were co-cultured for 24 h and leukemia cells were then obtained by combining all cells in the suspension and cells collected after washing the wells twice with phosphate buffered saline (PBS), stained with antibodies against CD45 (CD45-PE) and CD90 (CD90-APC) (both from BD Biosciences, San Jose, CA, USA), and sorted by FACS. The co-cultured cells were also treated with PD0325901 or LY294002. Leukemia cells were collected at 24 h by combining all cells in the suspension and cells collected after PBS washing.
ARC K/D and O/E cells were treated with cytarabine (Ara-C), ABT-737 (synthesized at the MD Anderson Cancer Center based on the published chemical structure [22] , or TNF-related apoptosis inducing ligand (TRAIL, Alexis Biochemicals, San Diego, CA, USA).
Taq-Man RT-PCR
Cell pellets were lysed in Trizol (Invitrogen). Total RNA was extracted by chloroform extraction and isopropanol precipitation and re-suspended in nuclease-free water. cDNA was prepared from total RNA in a mixture containing dNTP, random hexamers, and AMV reverse transcriptase and RNase inhibitor (both, Roche Applied Science, Indianapolis, IN, USA) at 42°C for 1 h. ARC was detected by using a TaqMan Gene Expression Assay (NOL3, Hs00358724_g1; Applied Biosystems, Inc. (ABI), Carlsbad, CA, USA) in an ABI 7900HT Fast RT-PCR system. Another TaqMan Gene Expression Assay (ABL1, Hs01104728_m1; ABI) was used as the loading control. The PCR reaction mixture contained cDNA, Taqman Gene Expression Assay reagent, and TaqMan Fast Universal PCR Master Mix (ABI). The reaction was initiated by a hold for 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. The abundance of ARC transcript relative to that of ABL1 was calculated using the 2 -DCt method, where DC t is the mean C t of ARC transcript minus the mean C t of the ABL1 transcript.
Immunofluorescence microscopy Cells were spun onto slides using a Statspin Cytofuge 12 or cultured on microscope slides and fixed with 4 % paraformaldehyde and permeabilized with 100 % methanol. Cells were incubated in blocking solution (3 % FBS/1 % bovine serum albumin/PBS). ARC rabbit polyclonal antibody (Cayman Chemical) was added to cells at 1:200 dilution in blocking solution. Cells were washed and secondary antibody (Alexa 488-tagged donkey anti-rabbit; Invitrogen, Eugene, OR, USA) was added in blocking solution. Cells were washed, stained with 4 0 ,6-diamidino-2-phenylindole (DAPI), washed again. Images were captured using an Olympus FV1000 laser scanning confocal microscope using a 1.45 NA 100 9 oil objective. Images were then imported and analyzed in Intelligent Imaging Innovations Slidebook 5.0 software. Briefly, masks were created from the 488 channel to identify the regions of cells. These masks were then watershed to separate neighboring cells. Once individual cells were identified in the segmentation mask the Sum was quantified for the 488 channel. This was then normalized per cell for three conditions (control, n = 165; PD0325901 treatment, n = 254; or LY294002 treatment, n = 148) for comparison purposes.
Phospho-flow analysis Cells were stained with live/dead fixable yellow dead cell stain kit (Invitrogen, Eugene, OR, USA), then fixed with 1.6 % formaldehyde, permeabilized with 0.1 % Triton X-100, and stored in methanol at 20°C awaiting further processing. Cells were stained with p-ERK 1/2-Alexa 488 and p-AKT (Ser473) 
Cell viability assay
Apoptosis was estimated by flow cytometric measurements of phosphatidyl serine with the annexin-V-Cy5 (AnnVCy5) staining (BD Biosciences). Membrane integrity was simultaneously assessed by 7-amino-actinomycin D (7AAD) exclusion in the annexin V-stained cells. Viable AML cells were counted via flow cytometry using CountBright absolute counting beads (Invitrogen). Signals were determined by using a FACSArray Bioanalyzer (BD Biosciences).
Western blot analysis
Protein levels in treated cells were determined by western blot analysis, as described previously [19] . ARC antibody was purchased from Imgenex (San Diego, CA, USA). Antibodies against p-ERK, ERK, p-AKT (Ser473), and AKT were obtained from Cell Signaling Technology (Danvers, MA, USA). Signals were detected by using the Odyssey Infrared Imaging System and quantitated by Odyssey software version 3.0 (LI-COR Biosciences, Lincoln, NE, USA). b-Actin was used as a loading control.
In vivo experiments NOD/SCID mice, 6 weeks old, were irradiated (2.5 Gy) and divided into two groups of nine mice/group under the institution approved protocol. The mice in one group were injected with 4.2 9 10 6 ARC O/E KG-1 cells and the mice in the other group with the same number of vector control cells via tail vein. NOD/SCID IL2Rc null (NSG) mice, 5 weeks old, were divided into two groups of seven mice/ group. The mice in one group were injected with 0.35 9 10 6 ARC K/D Molm13 cells and the mice in the other group with the same number of vector control cells via tail vein. Molm13 levels were assessed by flow cytometric measurement of human CD45
? cells in mouse blood samples. Mouse survival times were recorded and survival data were analyzed by the log-rank test.
Statistical analyses
All experiments were carried out in triplicate, and the results are expressed as the mean ± SEM, unless otherwise stated. The concentrations of agents that induced annexin-V positivity in 50 % of cells (EC 50 ) were calculated by using Calcusyn software (Biosoft, Ferguson, MO, USA). Expression of ARC in AML patient samples was summarized using mean, medium, standard deviation, and range.
Comparison of ARC between patient groups (e.g., RAS mutation status) was performed using Wilcoxon rank sum test. Statistical analysis was carried out using SAS version 9 (SAS Institute, Cary, NC). Statistical plotting was done using Spotfire S? version 8.2 (TIBCO, Somerville, MA). The Student t test was used to compare differences between the groups. All tests were two-sided and P values B 0.05 were considered statistically significant.
Results
ARC is upregulated by stromal cells via signaling pathways in AML cells
We first investigated whether ARC in AML cells is regulated by PI3K and/or MAPK signaling, which are two pathways that are constitutively active in AML. We treated OCI-AML3 cells with a MEK/ERK inhibitor PD0325901 (5 nM) or a PI3K inhibitor LY294002 (20 lM) and found that blockade of either MAPK or PI3K signaling led to time-dependent decreases in both ARC RNA and protein levels (Fig. 1a) . Similarly, inhibition of MAP3K1 expression by siRNA or inhibition of PI3K signaling by a dual PI3K and mTOR inhibitor BEZ235 currently under clinical development also decreased ARC expression (Fig. 1b) . In contrast, no change in ARC levels was observed when SRC kinase was inhibited by dasatinib (not shown). To confirm this finding and to assess the cellular localization of ARC, we also determined ARC levels in PD0325901 and LY294002 treated OCI-AML3 by immunofluorescence microscopy. As shown in Fig. 1c , ARC was localized both in nucleus and cytoplasm and its expression was decreased by MAPK or PI3K inhibition (P \ 0.0001).
We next co-cultured OCI-AML3 cells with MSCs and FACS-sorted CD45
? CD90 -AML cells. As shown in Fig. 1d , co-cultures with MSCs strongly increased ARC expression in CD45
? CD90 -leukemic cells. To determine whether the induction of ARC expression by MSCs is mediated through MAPK or PI3K signaling, we cultured OCI-AML3 cells with or without MSCs and treated them with PD0325901 (10 nM) or LY294002 (40 lM). We then examined MAPK and PI3K signaling and ARC expression by western blot analysis. As shown in Fig. 1e , co-culture greatly increased p-ERK and p-AKT levels in OCI-AML3 cells. PD0325901 or LY294002 decreased p-ERK or p-AKT levels in OCI-AML3 cells cultured alone and suppressed MSC co-culture-mediated induction of p-ERK or p-AKT in leukemia cells. Consistent with changes in MAPK and PI3K signaling, PD0325901 or LY294002 decreased ARC expression in OCI-AML3 cells and suppressed the MSC co-culture-mediated induction of ARC, suggesting that ARC is regulated by MAPK and PI3K signaling and upregulated by stroma via MAPK and PI3K signaling pathways. Unlike the data presented in Fig. 1d , we did not sort cells before performing Western blot analysis since the collected leukemia cells contained negligible amounts of CD90
? MSCs and the sorting procedure would diminish kinase activity. To confirm the levels of kinases we measured are from leukemia cells, and not from potentially contaminating MSCs, we also determined p-ERK and p-AKT by phospho-flow in CD45
? CD90 -cells (Fig. 1e) and confirmed the immune-blot data. Cell viability assessments for the cells treated with PD0325901 or LY294002 are shown below the graphs in Fig. 1e .
We then examined whether ARC is regulated by signaling pathways in samples from patients with AML. In the large sample set comprising 511 patients with newly diagnosed AML that we previously used to profile ARC 
CD90
-OCI-AML3 cells were determined by western blot. e OCI-AML3 cells were cultured alone or co-cultured with MSCs and treated with PD0325901 (10 nM) or LY294002 (40 lM) for 24 h. ERK, AKT, and ARC levels were determined by western blot in leukemia cells. p-ERK and p-AKT levels were also determined by phopho-flow in CD45
? CD90 -OCI-AML3 cells. Alone, leukemia cells are cultured alone in suspension; cocx, leukemia cells were co-cultured with MSCs; PD, PD0325901; LY, LY294002 expression [16] , 435 had known RAS mutation status. We analyzed ARC levels in RAS mutation positive (N = 64) and negative (N = 371) samples and found that samples with RAS mutations expressed significantly higher levels of ARC than samples without RAS mutations (P = 0.016, Fig. 2 ). Taken together, these findings suggest that ARC expression is regulated, at least in part, by MAPK and PI3K signaling mechanisms.
ARC protects AML cells from apoptosis induced by chemotherapy or inducers of intrinsic or extrinsic apoptosis Endogenous expression of ARC is extremely low in KG-1 and higher in OCI-AML3 and Molm13 AML cells. To investigate the role of ARC in apoptosis resistance in AML cells, we generated stable ARC O/E KG-1 and stable ARC K/D OCI-AML3 and Molm13 cells (Fig. 3a) and treated them with Ara-C or agents that selectively induce intrinsic (i.e., ABT-737) or extrinsic (i.e., TRAIL) apoptosis. We found that the ARC O/E cells were more resistant and ARC K/D cells more sensitive to Ara-C, ABT-737, and TRAIL than the respective controls (Fig. 3b) , suggesting that ARC expression in AML cells protects these cells from both intrinsic and extrinsic apoptotic stimuli. The EC 50 values from these assessments, relative to the respective vector controls, are shown in Fig. 3b . (Fig. 4b) . We also injected equal numbers of ARC K/D or vector control Molm13 cells into NSG mice and found that significantly fewer leukemia developed when NSG mice were injected with ARC knockdown as compared to control Molm13 cells (P = 0.005 and 0.03 at 2 and 3 weeks, respectively) (Fig. 4c ). There was a trend for prolonged survival of mice injected with ARC K/D cells, but it did not reach statistical significance (not shown). Limited knockdown of ARC may therefore not sufficiently change physiological apoptosis thresholds, which are regulated by many proteins, while overexpression resulted in significantly shorter survival of leukemia bearing mice.
Interestingly, we previously reported that when newly diagnosed AML patients (n = 511) were grouped based on their ARC levels determined by RPPA, the patients with high ARC had significantly shorter overall survival and event-free survival than the patients with low ARC [16] .
Discussion
In this study, we demonstrate that ARC is regulated by MAPK and PI3K signaling in AML cells, and that the BM microenvironment can increase ARC expression in AML Constitutive activation of MAPK and PI3K is common in AML, and this aberrant cell signaling is typically associated with poor clinical outcomes in AML patients [23] [24] [25] [26] [27] [28] . These signaling pathways play critical roles in cancer cell growth and survival via various mechanisms. For example, they can induce the expression of multiple antiapoptotic proteins such as Mcl-1, XIAP, and survivin [18, 19, 29] . The BM microenvironment is known to play critical roles in AML disease progression and in protecting leukemia cells from apoptosis induced by various therapeutic agents. It exerts its protective role in part by activating MAPK/PI3K signaling and by inducing the expression of antiapoptotic proteins. Our findings that ARC expression is regulated by MAPK and PI3K signaling, and that MSC co-culture stimulates MAPK/PI3K signaling and ARC expression, support the pro-survival role of ARC in AML cells.
RAS regulates multiple signaling pathways and it is frequently mutated in AML. RAS is reportedly mutated in 10-25 % patients with AML [30] [31] [32] [33] [34] . Proteomic analysis revealed that RAS-Raf-MAPK and PI3K signaling pathways were upregulated in AML patients with RAS mutations [35] . We observed that ARC expression was increased in samples from patients with RAS-mutated AML compared to patients with RAS-wild type AML, supporting the in vitro finding that ARC is regulated by MAPK and PI3K signaling. Our results are also consistent with a report that ARC is induced by RAS in a MEK/ERK-dependent manner in epithelial cancers [14] .
ARC was reported to be localized almost exclusively in the nuclei of various human and rat cancer cells. Conversely, in non-cancer cells it localizes to the cytoplasm [9] . We did not observe a restricted nuclear localization of ARC in OCI-AML3 cells, and it is not clear currently what this could mean for the relation to AML to other types of cancer. ARC's role as a protector of AML cells from both intrinsic and extrinsic apoptotic cell death was validated using ARC O/E and ARC K/D cells. Indeed, we found that high ARC levels promoted resistance to chemotherapy and apoptotic stimuli in the AML cells. This implies that targeting of ARC with small molecule inhibitors could perhaps directly induce apoptosis and/or sensitizes chemotherapy in AML. Nevertheless, high nuclear ARC in OCI-AML3 cells may suggest that ARC is stored in the nucleus and released into the cytoplasm as needed, or ARC has roles in the nucleus such as protecting cells from DNA damage or affecting the expression of other genes through protein-protein interactions that need to be further defined.
Together, our results demonstrate that ARC plays critical roles in AML growth and survival. ARC levels are regulated in AML cells by BM MSCs through various survival signaling pathways, protects leukemia cells from apoptosis induced by chemotherapy and agents that selectively induce intrinsic or extrinsic apoptosis, and promotes leukemia cell growth in vitro and in vivo, all of which may contribute to ARC being a poor prognostic factor in AML. Results suggest that ARC could be a novel target for treatment of AML.
